Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28540865 | 0.80 | CYP3A4 (0.47) | TSHRCYP3A4TDP1 | |
| SCHEMBL21111817 | 0.78 | CA1 (0.44) | TSHRTDP1 | |
| SCHEMBL14605205 | 0.78 | TSHR (0.33) | TSHRACHECYP3A4TDP1 | |
| SCHEMBL21111827 | 0.77 | GABRA1 (0.33) | CYP3A4TDP1 | |
| SCHEMBL21111873 | 0.77 | ACHE (0.43) | TSHRACHECYP3A4TDP1 | |
| SCHEMBL11056512 | 0.76 | TSHR (0.43) | TSHRACHECYP3A4TDP1 | |
| SCHEMBL21111876 | 0.76 | GABRA1 (0.35) | TSHRCYP3A4 | |
| SCHEMBL21111867 | 0.74 | IRAK4 (0.38) | ACHETDP1 | |
| SCHEMBL21111754 | 0.74 | ALDH1A1 (0.43) | TDP1 | |
| SCHEMBL21111849 | 0.73 | ACHE (0.44) | TSHRACHECYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919921-B2 | P-chiral phosphine ligands and use thereof for asymmetric synthesis | BASF SE | 2021-02-16 | — | — | US | disclosed |
| US-20190211040-A1 | P-CHIRAL PHOSPHINE LIGANDS AND USE THEREOF FOR ASYMMETRIC SYNTHESIS | BASF SE (DE) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211040-A1 | P-CHIRAL PHOSPHINE LIGANDS AND USE THEREOF FOR ASYMMETRIC SYNTHESIS | PLCD1, PLCB3, PHOSPHO1 | TSHR 3959/4885ACHE 64/4885CYP3A4 965/4885 |
| US-10919921-B2 | P-chiral phosphine ligands and use thereof for asymmetric synthesis | PLCD1, PLCB3, PHOSPHO1 | TSHR 3959/4885ACHE 64/4885CYP3A4 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.